{"name":"NeuShen Therapeutics","slug":"neushen-therapeutics","ticker":"","exchange":"","domain":"","description":"NeuShen Therapeutics is a biotechnology company focused on developing innovative treatments for neurological disorders. The company's lead candidate, NS-136 tablet, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNVQyZUFuNVQxV1VrbFZLRlllZkI5bjdfQzU5bjJGSk05M21OZW55Zk1pX29JUjAtWlBzQzhZX1VrVEJwYlN0QXBDWk8wT2o5YXI3ZHZTbDd0Slg2YXhXbmk0WjctVmlmdzRYY1lfZEJjVlZyamVKUlh0cnNMbDZwblFOdDAyWmltX3pzcDhXckZsRU85QTdIQWRpNVRzSjlzN0dWM1dGQ3lWUQ?oc=5","date":"2026-03-09","type":"trial","source":"Seeking Alpha","summary":"Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked (NASDAQ:XENE) - Seeking Alpha","headline":"Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked (NASDAQ:XENE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPYUNra1FLYjl3ajFwdXl1elJXWGFFcDJtUXJjUVA0LUlaMW1WVVJBZEItMW8zWFRqcDUyUTVjRTNtN1FEYmtSRWNMUUxIM3RvdHhYVnNrSGp0UWZnQ3pPRk9feUVFRzlod0ZuSFlIcUl3bFFrUmFDa1JQbHE4MlgxQkJ0QkdLT1BpZDNhQ3gxTEtvbUw1bXM4QWNSTVpfcGJQVFk2NkhWN2xScVZZU2J5RV90Z3VIN3FGV0NGNUVMSnpDai0zVHFIbnBzZjB6azFtRnliQnFR?oc=5","date":"2026-02-17","type":"pipeline","source":"Citeline News & Insights","summary":"Chinese ADC, Cell/Gene Therapy Biotechs Ride Funding Spree - Citeline News & Insights","headline":"Chinese ADC, Cell/Gene Therapy Biotechs Ride Funding Spree - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQblJ5dzZIekgtTGt0bzJyUXpmYklvT3duTVJDSFA4bV9Dd20zYmZBUUx3VW15WjdhYWxjb2g2UTk5Tm9VR1lWYlRwR1REZlNfcUU1MDNpc0l1OTIteHNuNkUyU3E2OERZZ1dXVGlJWVc5WHdhT2pnZTNrLXZMS05QYTR5M0hzRllReTEyVGY2enpUZldkMWtESG1oMk1nSmprY3IzR0M3blZ6X1FaRkZnN2VvcElCQWxzU3FsczVER2dfei1EWUJjUHFFVnMxSmZ5aUppOWxaWFhiQ1hjN2ViOWhGdm5fcTU2TFE?oc=5","date":"2024-10-09","type":"trial","source":"GlobeNewswire","summary":"Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight - GlobeNewswire","headline":"Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxObUVMN3ZTM2hEd3F1RVlNV1hfM3FBMi1MZ3JhUmlVaC12VkhyR1l6SVA2QU1tTFhWTEMtNlMyWE9SUmYwSHVFNWdZNTVTblZXa0llZkRCcjZ0NzRXdTVoc25NRElqdFAzV0xDczlNNVBCMEd3eTZ3SjdWOW5oWGZQSklrNEFRVDBQVnpKQmU3TDBCX2JtV0V0Ni1lVnJDWDRsazEwMVpvR0c1b3B0X1lHZHJqQ0RiQzdEdGZ6WlF5U0QyYXhtb0hIQlMyeVItejQyZ1Vjd1M5d1p5ekYtUVAxVXlR?oc=5","date":"2024-05-10","type":"trial","source":"BioPharma APAC","summary":"NeuShen Therapeutics Begins Phase I Trial of NS-136, a Potential Breakthrough in Schizophrenia Treatment - BioPharma APAC","headline":"NeuShen Therapeutics Begins Phase I Trial of NS-136, a Potential Breakthrough in Schizophrenia Treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNdEFNcHVGMnE0N1lRYlViOVlmQzllY0tIekxYS1BHNkhJR3ozRkQxUTAyRkF2MEEyVmlaaUFiTzVJVWNSRjJVUDdMVHBoLVlSZXY3aWZldzA5QWhOZ3Q2RFVVN1pCWHpEYXJBdzk5cTE2bWNvUkZyXzRZNE9JQUpId05Ua3I?oc=5","date":"2024-05-09","type":"trial","source":"Clinical Trials Arena","summary":"NeuShen begins dosing for Phase I trial of schizophrenia treatment - Clinical Trials Arena","headline":"NeuShen begins dosing for Phase I trial of schizophrenia treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQa1g1ZHExSHpTUGlaV0d5aEZNVldIUDJidnk5dGZZQmwxWlJLUUpab3djVDNYYVdhbVpvbWVaYjBWU0pSTTFZang3cElycUowQkhub045LUw5alp4cS16QUl6cUdDTmUxVzlkOHNFT0cza1ZDZm9MeE5ZWnZPbEs0SzRxVmNpX2hPdVVDLWNJdUlrYThJa1h2SUh0QVc0NFZpTmRLaUcxaWJBVWtTdnNieUdNVDNsUzJsblVvSkpYRGpSS3FfcUM4?oc=5","date":"2023-08-23","type":"earnings","source":"BioWorld News","summary":"NS-041, a novel KCNQ2/3 activator for the treatment of epilepsy, presented at ACS meeting - BioWorld News","headline":"NS-041, a novel KCNQ2/3 activator for the treatment of epilepsy, presented at ACS meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNeG1oNWtOb3MxZTZpc2t3dUcxS2ctbmdQVFE1NFdHZ1BkQWE4Wjd0bGpiaHVWV0Z6WDZwR29xZ2JESkNTRnNnZVNKZ25fVGZlZ2Z1OVF2RFRLbzJIclBHY0JwRWtydG9FN3FodEYwUnBxSUYzekFtQWJ6ajRNNmxuWmRVdXZiRVpSdjhqczd1RXRJM1ltcWtwcVBfTGdvOThaSTFrdzhqalNGeVRETWloV1hfcVI?oc=5","date":"2023-03-31","type":"pipeline","source":"UMass Chan Medical School","summary":"End AxD funds gene therapy research for Alexander disease - UMass Chan Medical School","headline":"End AxD funds gene therapy research for Alexander disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxPejgwZUg0ZWFrd2t2S0Y3QkFVM2NBNHlhREJZc1U3VUZiZlhFU1RrMXdLRE5VTU5VY3dLV2lBbXcwOFgwSl9DSGJpMWhlcmV3NFNxQnhRbDJnSTRhNFdzbXNseWJ3ckRzR21zTTFnd3ZQNVN6eUtsc3g4cEFrWm5ja0U2Vll4S3hOY0RFTGo1ejE1UGw5M05Yem5uLWwtQW9QRWtrSWZmc0pZT0YxckxHTW53d0dxT1ZGeFJiTWo0NVlsMVFZRE9rX1poWjh6eWdfcFRSTGMwbzVTVVlja256dDI0dXFxX0RORkFsQ2NDNTBGUFJTX1FyYw?oc=5","date":"2023-02-24","type":"deal","source":"UMass Chan Medical School","summary":"UMass Chan licensed siRNA chemistry to Aldena Therapeutics to develop therapies for dermatological diseases - UMass Chan Medical School","headline":"UMass Chan licensed siRNA chemistry to Aldena Therapeutics to develop therapies for dermatological diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPYmJuYkZSZEViU0V3Y1ZPTGJXZTdEcWJUZ2E1UkV1bVNKeGc1Mzd1ZlY1b3NYWk1sVklacnF6VFV5dG5FT0lSU09nOWREZWU1MUJtY1pPTnZUNlZBM3BoN1VrWHRtc0dfM3otNW1tcmQyRDZYQURVN1BqZmQxZjU0eXcxTlhMTEF6NDFhZ25iaHlEUk1oQmdlUUtMLTUtaHVBLVFEMEJIaUI5SGYyNkxHOGRzczRYQVNWUW9pcFA0dUY4Rnc?oc=5","date":"2023-02-03","type":"pipeline","source":"UMass Chan Medical School","summary":"NeuShen Therapeutics funds ALS research at UMass Chan Medical School - UMass Chan Medical School","headline":"NeuShen Therapeutics funds ALS research at UMass Chan Medical School","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPQVFQZDFYdmNnY2F2Q0RnbDBUdXR2TU12Zm5wMGZxYmVNdVAtcVphYlJBajBySnU4eHRwNXJEVzlza2UxNU9NS0EwdlhiOElsSEJ2VFlzeWdyR0JScEdvTE5IRVg5S1Q4TTE2cHc1NnVxRnRWVWRzdjlMZDhnclVsQ0F5LW9DNnRWaXJIT3hhTjdjZHd5NW1wM2QtT082WHA4Uk41QktlWVhUWkh6?oc=5","date":"2022-09-29","type":"pipeline","source":"PR Newswire","summary":"NeuShen Therapeutics Closes Pre-A Financing with ~$20M - PR Newswire","headline":"NeuShen Therapeutics Closes Pre-A Financing with ~$20M","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}